Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Chowers

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Antimicrobial Agents and Chemotherapy|February 9, 2012
Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infectionRonen Ben-Ami, Keren Olshtain-Pops, Michal Krieger, et al.
Viruses|December 23, 2023
Factors Associated with Virological Failure in First-Line Antiretroviral Therapy in Patients Diagnosed with HIV-1 between 2010 and 2018 in IsraelTali Wagner, Itzchak Levy, Daniel Elbirt, et al.
Viruses|January 22, 2022
Epidemiology and Transmitted HIV-1 Drug Resistance among Treatment-Naïve Individuals in Israel, 2010-2018Tali Wagner, Neta S Zuckerman, Tami Halperin, et al.
Antimicrobial Agents and Chemotherapy|September 15, 2010
National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamasesDror Marchaim, Tamar Gottesman, Orna Schwartz, et al.
Diagnostic Microbiology and Infectious Disease|July 19, 2011
Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapyVered Schechner, Tamar Gottesman, Orna Schwartz, et al.
Plos One|August 25, 2015
A Population-Structured HIV Epidemic in Israel: Roles of Risk and EthnicityZehava Grossman, Boaz Avidor, Zohar Mor, et al.
Plos One|January 30, 2014
Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypesZehava Grossman, Jonathan M Schapiro, Itzchak Levy, et al.
Nature Communications|July 29, 2023
Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2Tomer Hertz, Shlomia Levy, Daniel Ostrovsky, et al.
Cancer Medicine|February 24, 2024
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximabTali Shafat, Daniel Grupel, Tzvika Porges, et al.
Vaccine|December 14, 2021
Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)Mark A Katz, Efrat Bron Harlev, Bibiana Chazan, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Antimicrobial Agents and Chemotherapy|February 9, 2012
Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infectionRonen Ben-Ami, Keren Olshtain-Pops, Michal Krieger, et al.
Viruses|December 23, 2023
Factors Associated with Virological Failure in First-Line Antiretroviral Therapy in Patients Diagnosed with HIV-1 between 2010 and 2018 in IsraelTali Wagner, Itzchak Levy, Daniel Elbirt, et al.
Viruses|January 22, 2022
Epidemiology and Transmitted HIV-1 Drug Resistance among Treatment-Naïve Individuals in Israel, 2010-2018Tali Wagner, Neta S Zuckerman, Tami Halperin, et al.
Antimicrobial Agents and Chemotherapy|September 15, 2010
National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamasesDror Marchaim, Tamar Gottesman, Orna Schwartz, et al.
Diagnostic Microbiology and Infectious Disease|July 19, 2011
Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapyVered Schechner, Tamar Gottesman, Orna Schwartz, et al.
Plos One|August 25, 2015
A Population-Structured HIV Epidemic in Israel: Roles of Risk and EthnicityZehava Grossman, Boaz Avidor, Zohar Mor, et al.
Plos One|January 30, 2014
Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypesZehava Grossman, Jonathan M Schapiro, Itzchak Levy, et al.
Nature Communications|July 29, 2023
Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2Tomer Hertz, Shlomia Levy, Daniel Ostrovsky, et al.
Cancer Medicine|February 24, 2024
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximabTali Shafat, Daniel Grupel, Tzvika Porges, et al.
Vaccine|December 14, 2021
Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)Mark A Katz, Efrat Bron Harlev, Bibiana Chazan, et al.
Pageof 8